- Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
-
Shimizu H, Fujii T, Hibiya S, Motobayashi M, Suzuki K, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2512107
- Intest Res.
- 2021 Jan;19(1):115-118.
- doi: 10.5217/ir.2020.00030
-
- CITED
-
- Close
- SHARE
-
- Close
- Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study
-
Shimizu H, Aonuma Y, Hibiya S, Kawamoto A, Takenaka K, Fujii T, Saito E, Nagahori M, Ohtsuka K, Okamoto R
- KMID: 2558196
- Intest Res.
- 2024 Jul;22(3):369-377.
- doi: 10.5217/ir.2023.00194
Background/Aims: The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of... -
- CITED
-
- Close
- SHARE
-
- Close
- Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy
-
Kawamoto A, Takenaka K, Hibiya S, Kitazume Y, Shimizu H, Fujii T, Saito E, Ohtsuka K, Okamoto R
- KMID: 2551279
- Intest Res.
- 2024 Jan;22(1):65-74.
- doi: 10.5217/ir.2023.00092
Background/Aims: Endoscopic activity confirmed by enteroscopy is associated with poor clinical outcome in Crohn’s disease (CD). We investigated which of the existing biomarkers best reflects endoscopic activity in CD patients... -
- CITED
-
- Close
- SHARE
-
- Close
